Literature DB >> 24912493

Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia.

A D Stan1, S Ghose1, C Zhao2, K Hulsey2, P Mihalakos1, M Yanagi1, S U Morris3, J J Bartko4, C Choi2, C A Tamminga1.   

Abstract

Hippocampal dysfunction in schizophrenia is widely acknowledged, yet the mechanism of such dysfunction remains debated. In this study we investigate the excitatory and inhibitory hippocampal neurotransmission using two complementary methodologies, proton magnetic resonance spectroscopy (MRS) and tissue biochemistry, sampling individuals with schizophrenia in vivo and postmortem hippocampal tissue in vitro. The results show significantly lower glutamate concentrations in hippocampus in schizophrenia, an in vivo finding mirrored by lower GluN1 protein levels selectively in the dentate gyrus (DG) in vitro. In a mouse model with a DG knockout of the GRIN1 gene, we further confirmed that a selective decrease in DG GluN1 is sufficient to decrease the glutamate concentrations in the whole hippocampus. Gamma-aminobutyric acid (GABA) concentrations and GAD67 protein were not significantly different in hippocampus in schizophrenia. Similarly, GABA concentrations in the hippocampi of mice with a DG knockout of the GRIN1 gene were not significantly different from wild type. These findings provide strong evidence implicating the excitatory system within hippocampus in the pathophysiology of schizophrenia, particularly indicating the DG as a site of pathology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24912493     DOI: 10.1038/mp.2014.54

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  49 in total

Review 1.  Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies.

Authors:  R Grant Steen; Courtney Mull; Robert McClure; Robert M Hamer; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2006-06       Impact factor: 9.319

2.  Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.

Authors:  Lawrence S Kegeles; Xiangling Mao; Arielle D Stanford; Ragy Girgis; Najate Ojeil; Xiaoyan Xu; Roberto Gil; Mark Slifstein; Anissa Abi-Dargham; Sarah H Lisanby; Dikoma C Shungu
Journal:  Arch Gen Psychiatry       Date:  2012-01-02

3.  NMDA-dependent modulation of CA1 local circuit inhibition.

Authors:  H C Grunze; D G Rainnie; M E Hasselmo; E Barkai; E F Hearn; R W McCarley; R W Greene
Journal:  J Neurosci       Date:  1996-03-15       Impact factor: 6.167

4.  Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis.

Authors:  P Fusar-Poli; J M Stone; M R Broome; I Valli; A Mechelli; M A McLean; D J Lythgoe; R L O'Gorman; G J Barker; P K McGuire
Journal:  Arch Gen Psychiatry       Date:  2011-05-02

5.  Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging.

Authors:  Nathan L Hutcheson; Meredith A Reid; David M White; Nina V Kraguljac; Kathy B Avsar; Mark S Bolding; Robert C Knowlton; Jan A den Hollander; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2012-07-23       Impact factor: 4.939

6.  Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders.

Authors:  Mia Thompson; Cynthia Shannon Weickert; Eugene Wyatt; Maree J Webster
Journal:  J Psychiatr Res       Date:  2009-03-24       Impact factor: 4.791

7.  Molecular evidence for mitochondrial dysfunction in bipolar disorder.

Authors:  Christine Konradi; Molly Eaton; Matthew L MacDonald; John Walsh; Francine M Benes; Stephan Heckers
Journal:  Arch Gen Psychiatry       Date:  2004-03

Review 8.  In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function.

Authors:  Douglas L Rothman; Kevin L Behar; Fahmeed Hyder; Robert G Shulman
Journal:  Annu Rev Physiol       Date:  2002-05-01       Impact factor: 19.318

9.  De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia.

Authors:  G Kirov; A J Pocklington; P Holmans; D Ivanov; M Ikeda; D Ruderfer; J Moran; K Chambert; D Toncheva; L Georgieva; D Grozeva; M Fjodorova; R Wollerton; E Rees; I Nikolov; L N van de Lagemaat; A Bayés; E Fernandez; P I Olason; Y Böttcher; N H Komiyama; M O Collins; J Choudhary; K Stefansson; H Stefansson; S G N Grant; S Purcell; P Sklar; M C O'Donovan; M J Owen
Journal:  Mol Psychiatry       Date:  2011-11-15       Impact factor: 15.992

10.  Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network.

Authors:  Thomas J McHugh; Matthew W Jones; Jennifer J Quinn; Nina Balthasar; Roberto Coppari; Joel K Elmquist; Bradford B Lowell; Michael S Fanselow; Matthew A Wilson; Susumu Tonegawa
Journal:  Science       Date:  2007-06-07       Impact factor: 47.728

View more
  36 in total

Review 1.  Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders.

Authors:  Jennifer H Foss-Feig; Brendan D Adkinson; Jie Lisa Ji; Genevieve Yang; Vinod H Srihari; James C McPartland; John H Krystal; John D Murray; Alan Anticevic
Journal:  Biol Psychiatry       Date:  2017-03-14       Impact factor: 13.382

2.  Transmembrane protein 108 is required for glutamatergic transmission in dentate gyrus.

Authors:  Hui-Feng Jiao; Xiang-Dong Sun; Ryan Bates; Lei Xiong; Lei Zhang; Fang Liu; Lei Li; Hong-Sheng Zhang; Shun-Qi Wang; Ming-Tao Xiong; Mihir Patel; Alexis M Stranahan; Wen-Cheng Xiong; Bao-Ming Li; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

3.  Developmental expression of mGlu2 and mGlu3 in the mouse brain.

Authors:  Caitlin E McOmish; Elena Y Demireva; Jay A Gingrich
Journal:  Gene Expr Patterns       Date:  2016-11-04       Impact factor: 1.224

4.  Alterations in hippocampal connectivity across the psychosis dimension.

Authors:  Niyatee Samudra; Elena I Ivleva; Nicholas A Hubbard; Bart Rypma; John A Sweeney; Brett A Clementz; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga
Journal:  Psychiatry Res       Date:  2015-06-16       Impact factor: 3.222

5.  Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.

Authors:  Juan R Bustillo; Thomas Jones; Hongji Chen; Nicholas Lemke; Christopher Abbott; Clifford Qualls; Shannon Stromberg; Jose Canive; Charles Gasparovic
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

Review 6.  Translating the MAM model of psychosis to humans.

Authors:  Gemma Modinos; Paul Allen; Anthony A Grace; Philip McGuire
Journal:  Trends Neurosci       Date:  2014-12-30       Impact factor: 13.837

Review 7.  Schizophrenia: Evidence implicating hippocampal GluN2B protein and REST epigenetics in psychosis pathophysiology.

Authors:  C A Tamminga; R S Zukin
Journal:  Neuroscience       Date:  2015-07-23       Impact factor: 3.590

8.  Loss of pattern separation performance in schizophrenia suggests dentate gyrus dysfunction.

Authors:  Tanusree Das; Elena I Ivleva; Anthony D Wagner; Craig E L Stark; Carol A Tamminga
Journal:  Schizophr Res       Date:  2014-08-28       Impact factor: 4.939

Review 9.  Cell-based therapies for the treatment of schizophrenia.

Authors:  Jennifer J Donegan; Daniel J Lodge
Journal:  Brain Res       Date:  2016-08-18       Impact factor: 3.252

Review 10.  Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies.

Authors:  Remmelt R Schür; Luc W R Draisma; Jannie P Wijnen; Marco P Boks; Martijn G J C Koevoets; Marian Joëls; Dennis W Klomp; René S Kahn; Christiaan H Vinkers
Journal:  Hum Brain Mapp       Date:  2016-05-04       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.